Terbinafine Hydrochloride

Terbinafine hydrochloride is an allylamine-based broad-spectrum antifungal drug for dermatology. It was successfully developed by Novartis Pharmaceuticals of Switzerland in the 1980s and was first launched in the UK in 1991. It was approved as an OTC drug by the US FDA in 1996 and was launched in the United States in the same year. Currently, it is sold in more than 90 countries around the world. It can specifically interfere with the early biological decomposition of fungal sterols, selectively inhibit the activity of fungal squalene epoxygenase, and hinder the squalene epoxidation reaction during the formation of fungal cell Chemicalbook membranes, thereby achieving killing Kill or inhibit fungi. It is suitable for treating cutaneous candidiasis, such as tinea manuum, tinea pedis, tinea cruris, tinea corporis and tinea versicolor. It is also the best drug for treating onychomycosis. In 2000, terbinafine hydrochloride entered the first batch of OTC catalogs announced by the state. This product is an antifungal drug that has a strong effect on superficial fungal infections and can cure most skin fungal diseases when applied externally.

Terbinafine hydrochloride is an allylamine-based broad-spectrum antifungal drug for dermatology. It was successfully developed by Novartis Pharmaceuticals of Switzerland in the 1980s.

First launched in the UK in 1991. It was approved as an OTC drug by the US FDA in 1996 and was launched in the United States in the same year.